Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.

Inhibitors of the human immunodeficiency virus type 1 protease represent a promising class of antiviral drugs for the treatment of AIDS, and several are now in clinical trials. Here, we report the in vitro selection of viral variants with decreased sensitivity to a C2-symmetric protease inhibitor (A...

Deskribapen osoa

Xehetasun bibliografikoak

Argitaratua izan da:	J Virol
Egile Nagusiak:	Ho, D D, Toyoshima, T, Mo, H, Kempf, D J, Norbeck, D, Chen, C M, Wideburg, N E, Burt, S K, Erickson, J W, Singh, M K
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	American Society for Microbiology (ASM) 1994
Gaiak:	Research Article
Sarrera elektronikoa:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC236669/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8107264/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.68.3.2016-2020.1994
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!